851095-32-4

851095-32-4 structure

Name: STX-0119
Chemical Name: 4-Quinolinecarboxamide, N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-2-phenyl
CAS Number: 851095-32-4
Molecular Formula: C₂₂H₁₄N₄O₃
Molecular Weight: 382.37200
Catalog: Signaling Pathways JAK/STAT Signaling STAT
Create Date: 2018-06-12 18:18:12
Modify Date: 2025-08-25 13:22:23
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM[1].

Name	4-Quinolinecarboxamide, N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-2-phenyl
Synonyms	Stx 0119

Description	STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM[1].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> STAT Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> STAT
Target	STAT3:74 μM (IC50, STAT3 transcription)
In Vitro	STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells[1]. STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins[1]. Western Blot Analysis[1] Cell Line: MDA-MB-468 cells Concentration: 10, 20 and 50 μM Incubation Time: 24 h Result: Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.
In Vivo	STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice[1]. The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration[1]. Animal Model: Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model[1] Dosage: 160 mg/kg Administration: Oral gavage, daily for 4 days Result: Suppressed the growth of SCC-3 cells significantly on the fourth day.